Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC

In the originally published version of this manuscript, there were multiple errors in formatting and content. Figures 1, 2, 4, 5, 6, 12, 19, and 20 have been replaced with corrected versions. The wording of the recommendation "Tafamidis is recommended in patients with genetic testing proven hereditary hTTR-CMP and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality." has been corrected to: "Tafamidis is recommended in patients with genetic testing proven hTTR-CA and NYHA class I or II symptoms to reduce symptoms, CV hospitalization and mortality." The wording of the recommendation "Monitoring of pulmonary artery pressure using a wireless haemodynamic monitoring system may be considered in symptomatic patients with HFrEF (LVEF ≤ 35%) in order to improve clinical outcomes." has been corrected to: "Monitoring of pulmonary artery pressure using a wireless haemodynamic monitoring system may be considered in symptomatic patients with HF in order to improve clinical outcomes." Minor changes have also been made to the formatting and content of the text, tables, and footnotes.